Name: Semnur Pharmaceuticals Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Semnur Pharmaceuticals Inc 's Comment on Competition and Industry Peers

The competitive landscape for SP-102 includes pharmaceutical, biotechnology, and specialty pharmaceutical companies with drug pipelines, capital, and research and development organizations. SP-102 seeks to become the first FDA-approved epidural steroid injection (ESI) for the treatment of sciatica, as there are currently no FDA-approved ESIs for this indication. It will compete with opioid pain medications, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, antidepressants, anticonvulsants, surgical procedures such as nerve blocks and transcutaneous electrical nerve stimulation, as well as off-label or unapproved branded and generic injectable steroids. The market is anticipated to become increasingly competitive. The company previously purchased sodium hyaluronate from Genzyme under a supply agreement that ended on May 31, 2024, and is currently in discussions with Sanofi, an affiliate of Genzyme, regarding future supply.

<< See the full list of SMNR competitors

Sources: Semnur Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Semnur Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Semnur Pharmaceuticals Inc 's

Competitiveness

SMNR Sales vs. its Competitors Q2 2026

Net Income Comparison

Semnur Pharmaceuticals Inc 's Comment on Competition and Industry Peers

Publicly Traded Peers of Semnur Pharmaceuticals Inc